| oditrasertib (DNL788) / Denali Therap, Sanofi |
2021-004156-42: Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS) |
|
|
| Ongoing | 2 | 261 | Europe | SAR443820, Film-coated tablet | Sanofi-aventis recherche & développement, Sanofi-Aventis recherche & développement | Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2022-000049-34: Phase 2 study of SAR443820 in participants with multiple sclerosis (MS) |
|
|
| Ongoing | 2 | 280 | Europe | SAR443820, Film-coated tablet | Sanofi-aventis recherche & développement, Sanofi-Aventis recherche & développement | Multiple sclerosis Esclerosis Múltiple, Multiple sclerosis Esclerosis Múltiple, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Terminated | 2 | 305 | Europe, Canada, Japan, US, RoW | SAR443820, Placebo | Sanofi, Sanofi-Aventis recherche & développement | Amyotrophic Lateral Sclerosis | 03/24 | 03/24 | | |
NCT05630547: A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis |
|
|
| Active, not recruiting | 2 | 174 | Europe, Canada, RoW | SAR443820, Placebo | Sanofi | Multiple Sclerosis | 09/25 | 09/25 | | |
NCT05795907: Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants |
|
|
| Completed | 1 | 84 | US | SAR443820, Placebo | Sanofi | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 07/21 | 07/21 | | |
NCT05797701: A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2) |
|
|
| Completed | 1 | 18 | US | SAR443820 | Sanofi | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 09/21 | 09/21 | | |
NCT05797753: A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B) |
|
|
| Completed | 1 | 16 | US | SAR443820, Erythromycin ethyl succinate, Itraconazole | Sanofi | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 07/22 | 07/22 | | |